Sociedad Americana de Hirudoterapia

Prognostic factors for attempted finger replantation and revascularisation

Retrospective study published in J Hand Surg Asian Pac Vol (2023)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportEnsayos clínicosLu et al. · The journal of hand surgery Asian-Pacific volume, 2023

Abstract

Background: The aim of this study was to evaluate the impact of variant factors on finger replantation and revascularisation after traumatic amputation, which also included duty shift and the level of main operator. Methods: To determine the prognostic factors for the survival rate of finger replantation and revascularisation after traumatic finger amputation, we retrospectively reviewed the cases of finger replantation conducted from January 2001 to December 2017. Data collected consisted of the basic information of the patients, trauma-related factors, details of the operation and treatment outcomes. Descriptive statistics and data analysis was performed to assess outcomes. Results: In total, 150 patients with 198 replanted digits were enrolled in this study. The median age of the participants was 42.5 years, and 132 (88%) patients were men. The overall successful replantation rate was 86.4%. Seventy-three (36.9%) digits had Yamano type 1 injury; 110 (55.6%), Yamano type 2 injury and 15 (7.6%), Yamano type 3 injury. In total, 73 (36.9%) digits were completely amputated and 125 (63.1%) were not. Half of the replantation procedures (101, 51.0%) were performed during night shift (16:00-00:00), 69 (34.8%) during day shift (08:00-16:00) and 28 (14.1%) during graveyard shift (00:00-08:00). Multivariate logistic regression demonstrated that the trauma mechanism and type of amputation (complete vs. incomplete) significantly affect the survival rate of replantation. Conclusions: The trauma mechanism and type of amputation (complete vs. incomplete) significantly affect the survival rate of replantation. Other factors including duty shift and the level of operator did not reach statistically significance. Further studies must be conducted to validate the results of the current study. Level of Evidence: Level III (Prognostic).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsMaleHumansAdultFemaleRetrospective StudiesPrognosisAmputation, TraumaticReplantationFinger InjuriesAmputation, Surgical

Resumen

Retrospective analysis of prognostic factors for attempted finger replantation and revascularization outcomes.

Por qué esto importa para la hirudoterapia

Este estudio retrospectivo revisó 150 pacientes (198 dedos) que se sometieron a reimplante o revascularización de dedos durante un período de 17 años, encontrando una tasa de éxito global del 86,4% e identificando el mecanismo del traumatismo y el carácter completo de la amputación como factores pronósticos significativos, mientras que el turno de guardia y el nivel del operador no fueron significativos. Para el dominio de ASH, el artículo es relevante solo de manera indirecta: el reimplante digital es un contexto en el cual la terapia con sanguijuelas medicinales puede usarse como adyuvante para la congestión venosa, pero el resumen no menciona sanguijuelas ni hirudoterapia. El estudio se centra en factores pronósticos quirúrgicos y relacionados con la lesión. No se presenta evidencia directa sobre la terapia con sanguijuelas ni sobre el secretoma de la sanguijuela.

Citación

Prognostic factors for attempted finger replantation and revascularisation.

Lu et al. · The journal of hand surgery Asian-Pacific volume, 2023

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.